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Bullous pemphigoid is a subepidermal bullous disease of skin and mucosae associated with autoantibodies to
BP180. To characterize the humoral response to BP180, we generated a random BP180 epitope library displayed on
k bacteriophage. After validation of the library by epitope mapping of three BP180-speciﬁc monoclonal antibodies,
15 novel or known BP180 epitopes were identiﬁed using 10 bullous pemphigoid serum samples. Fifty-seven
bullous pemphigoid and 81 control sera were then assayed against the selected epitopes. Thirty-one out of 57
(54%) bullous pemphigoid sera reacted with at least an additional antigenic site other than the NC16A, within the
extracellular (37%) and intracellular (28%) domains of BP180. In addition, the reactivity with extracellular epitopes
of BP180 contained within the residue stretches 508–541 and 1331–1404 appeared to be related to the presence of
both skin and mucosal involvement. Finally, a preliminary analysis of the epitope pattern in the disease course
indicated that bullous pemphigoid patients exhibit a speciﬁc reactivity pattern, and that binding to intracellular
epitopes of BP180, in addition to NC16A, may be detectable at an early clinical stage. Our ﬁndings provide novel
insights into the pathophysiology of bullous pemphigoid and show the potential of the utilized approach as a tool
for a rapid diagnosis of bullous pemphigoid patients and their management.
Key words: autoimmunity/BP180/epitope spreading/hemidesmosome/phage display.
J Invest Dermatol 122:103 –110, 2004
Bullous pemphigoid (BP) is an autoimmune subepidermal
bullous disease of the skin and mucosae that typically
affects the elderly. BP is associated with tissue-bound and
circulating IgG autoantibodies directed against the basal
membrane zone (BMZ) of stratified epithelia (Liu and Diaz,
2001). Patient autoantibodies react with BP230 and BP180
(Stanley et al, 1988; Diaz et al, 1990), two components of
the junctional adhesion complex called hemidesmosome.
BP230 (also called BPAG1) is a cytoplasmic protein
implicated in the organization of the keratin filament
network. In contrast, BP180 (BP antigen 2 or type XVII
collagen) is a transmembrane protein that consists of a
globular cytoplasmic domain and a large extracellular
region containing 15 collagenous domains that lead to
homotrimer formation (Giudice et al, 1992; Hirako et al,
1996; Scha¨cke et al, 1998). This protein contributes to the
assembly and stabilization of hemidesmosomes (Hopkinson
et al, 1995; Borradori et al, 1997). Mutations in the BP180
gene underlie the non-Herlitz variant of junctional epider-
molysis bullosa, an inherited blistering disorder character-
ized by skin fragility and defective dermal–epidermal
adhesion, an observation attesting to the importance of
BP180 in maintenance of skin integrity (McGrath et al,
1995).
The vast majority of BP patients possess IgG auto-
antibodies directed against an immunodominant region
mapped in the membrane-proximal noncollagenous region
of the BP180 ectodomain, the NC16A domain (Zillikens et
al, 1997a). Additional antigenic reactive sites, however,
located both in the intracellular domain (ICD) and extra-
cellular domain (ECD) of BP180, have been recently
described (Murakami et al, 1998; Nakatani et al, 1998;
Egan et al, 1999, 2001; Nie and Hashimoto, 1999; Perriard
et al, 1999; Schumann et al, 2000). Several observations
indicate that autoantibodies to BP180 are pathogenic. In
particular (1) the passive transfer of rabbit IgG antibodies,
raised against an extracellular region of murine BP180
homologous with the human immunodominant NC16A
domain, into neonatal mice induces a blistering disorder
mimicking BP (Liu et al, 1993); (2) in gestational pemphigoid,
a disease closely related to BP occurring during pregnancy,
the transplacentar transfer of anti-BP180 autoantibodies
from the mother into the neonate can cause a transient
bullous eruption (Jordon et al, 1976); and finally (3) the level
of autoantibodies against BP180 appears to be related to
Abbreviations: AA, amino acids; BCIP, 5-bromo-4-chloro-3-
indolyl phosphate; BP, bullous pemphigoid; DIF, direct
immunofluorescence; ECD, extracellular domain; GST,
glutathione S-transferase; ICD, intracellular domain; IIF,
indirect immunofluorescence; NBT, nitroblue tetrazolium;
NHI, normal healthy individuals.
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the activity and extent of the disease (Haase et al, 1998;
Schmidt et al, 2000; Amo et al, 2001; Hofmann et al, 2002;
Kobayashi et al, 2002).
Based on these and other findings (Hall et al, 1993) it is
thought that autoantibodies to the ECD of BP180 are
pathogenically critical, whereas development of antibodies
against intracellular antigenic determinants on BP230 and
on BP180 is a secondary event in the context of an ‘‘epitope
spreading phenomenon’’ (Chan et al, 1998). A comprehen-
sive characterization of the antigenic determinants of
BP180 recognized by BP autoantibodies, however, has
not been carried out so far. Furthermore, no data are
available about the pattern of reactivity against different
epitopes of BP180 in the disease course. A distinct pattern
of reactivity is likely to be critical for both the initiation and
perpetuation of the disease and may result in a distinct
clinical phenotype (Hofmann et al, 2002).
The phage display technology is based on the construc-
tion of molecular libraries that can be searched by affinity
selection with a target molecule. The general limitation of a
prokaryotic system for epitope mapping studies is that
post-translational modifications such as hydroxylation and
glycosylation do not occur. Nevertheless, this technology
has recently been successfully employed to identify
disease-specific antigens of various autoimmune disorders
such as Sjo¨gren’s syndrome and vitiligo (Niwa et al, 2000;
Kemp et al, 2002).
In this study, to gain better insight into the pathophysiol-
ogy of BP, we have prepared a BP180 random epitope
library on l bacteriophage to identify disease-specific
epitopes on BP180. We characterized, in addition to known
antigenic reactive sites, several novel epitopes located
within both the ICD and ECD of BP180 that are significantly
recognized by a large panel of BP patient sera. Further-
more, the reactivity profile in BP patients appeared to relate
to a distinct clinical phenotype. Finally, we provide
preliminary evidence that reactivity with intracellular epi-
topes of BP180, in addition to that with NC16A, may be
detectable in an early stage of the disease.
Discussion
In this study we have utilized the l phage display
technology for the analysis of the humoral response to
BP180 in BP, the most frequent subepidermal autoimm-
mune disorder of the skin. By testing a representative
BP180 random epitope library we have been able (1) to
precisely characterize the epitopes recognized by three
anti-BP180-specific MoAb; (2) to finely map novel antigenic
regions within both the ICD and ECD of BP180 that are
targeted with significant frequency by a large panel of BP
serum samples; (3) to correlate reactivity with specific
extracellular epitopes of BP180 with a distinct clinical
phenotype. Finally, our findings indicate that in the course
of the disease patients exhibit a distinct epitope pattern and
that reactivity against various intracellular epitopes, in
addition to that against NC16A, can be observed even in
the early stage of the disease.
We first validated our library by mapping the epitopes
recognized by three BP180-specific MoAb: 1A8c, 233, and
1D1. In extension to previous studies, our approach allowed
us to substantially narrow the location of the epitopes for
these MoAb (Borradori et al, 1997; Hirako et al, 1998). These
findings will prove useful for future functional studies of
BP180, such as cell adhesion or hemidesmosome assem-
bly inhibition assays.
By using the generated random BP180 epitope l library,
we have been able to identify and further map known as
well as novel antigenic primary sequences within both the
ICD and ECD of BP180. First, in line with previous findings,
60% of the 57 tested BP serum samples bound to an
epitope spanning residues 508–541, located within the
immunodominant NC16A domain (Giudice et al, 1994).
Recent studies have shown that the majority of BP serum
samples recognize a similar region within the NC16A
domain (Zillikens et al, 1997b; Kromminga et al, 2002).
Noteworthy, 54% of the tested BP serum samples
recognized at least an additional antigenic reactive site
other than the NC16A domain. Specifically, 21 BP sera
(37%) reacted with other extracellular epitopes, whereas 16
(28%) bound intracellular epitopes of BP180. These findings
correlate well with recent studies showing that reactivity to
BP180 is not limited to the NC16A domain, but involves
additional antigenic sites within both the ICD and ECD of
BP180 (Murakami et al, 1998; Nakatani et al, 1998; Egan et
al, 1999, 2001; Nie and Hashimoto, 1999; Perriard et al,
1999; Schumann et al, 2000). Specifically, the frequency of
recognition (23%) of the two novel epitopes (AA 915–985
and AA 1080–1107) in the BP180 mid-portion was similar to
that previously reported for a large recombinant fragment of
BP180 spanning residues 850–1171 (Nie and Hashimoto,
1999). It should be noted that recognition of these two
representative epitopes was also confirmed by dot blot
analysis using GST fusion proteins, demonstrating that the
detected reactivity does not depend on the molecular
context used. In the COOH-terminal region of the ECD of
BP180, two additional overlapping epitopes (AA 1350–1387
and AA 1354–1406) were identified. These two epitopes are
contained in the region spanning AA 1331–1404, which was
recognized by 19% of our 57 BP serum samples, a
frequency comparable to that reported for a recombinant
protein consisting of residues 1365–1413 (Murakami et al,
1998). In the ICD, 21% of the tested BP serum samples
bound to either AA 151–170 or AA 176–203, two closely
located epitopes comprising less than 30 amino acids, and
10.5% of BP sera recognized the amino acid stretch 299–
354. These results strongly suggest that the central portion
of the ICD of BP180 is highly immunogenic. This idea is
further supported by the observation that the epitope AA
151–170 was also recognized by 1A8c MoAb, indicating
that this site is also immunogenic in mice.
Our results provide evidence that in BP the autoantibody
response to BP180 is frequently directed to several
epitopes, the pattern of which may substantially vary
among patients. In this context, recent studies suggest
that a distinct pattern of reactivity with BP180 is related to a
distinct clinical involvement, such as disease extent or
presence of mucosal lesions (Balding et al, 1996; Hofmann
et al, 2002). Our findings confirm that mucosal involvement
in BP is associated with a distinct epitope pattern (see Table
IV). Specifically, reactivity with two extracellular epito-
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pes consisting of a 34 AA stretch in the NC16A domain (AA
508–541) and a COOH-terminal 74 AA stretch (AA 1331–
1404) was significantly associated with mucosal involve-
ment, suggesting that autoantibody reactivity with multiple
regions of the ECD of BP180 contributes to the develop-
ment of mucosal lesions.
Findings obtained in various animal models have
suggested that autoimmune diseases are characterized by
an ‘‘early’’ phase, in which the immune response is
restricted to one or two epitopes within the antigen
(dominant epitopes), and a ‘‘late’’ phase, in which the
specificity spreads to additional subdominant epitopes
(epitope spreading) (Chan et al, 1998; Vanderlugt and Miller,
2002). Some evidence for the occurrence of an epitope
spreading phenomenon has also been reported in humans
(Tuohy et al, 1999; Bonifacio et al, 2000).
In BP disease, based on the results of in vitro studies
(Sitaru et al, 2002), in vivo animal models (Hall et al, 1993;
Liu et al, 1993), and clinical observations (Haase et al, 1998;
Schmidt et al, 2000; Amo et al, 2001; Hofmann et al, 2002;
Kobayashi et al, 2002), it has been speculated that
autoantibodies to the NC16 subdomain are pathogenically
critical, whereas development of antibodies against intra-
cellular antigenic determinants on BP180 (and BP230) is a
secondary event in the context of an ‘‘epitope spreading
phenomenon’’ (Chan et al, 1998). Nevertheless, our study
discloses some novel, unexpected findings. First, untreated
BP patients with a disease duration of 3 mo exhibited a
trend, although not significant, to display higher binding
reactivity with intracellular epitopes than patients with a
disease duration greater than 3 mo. Second, preliminary
analysis of the epitope pattern in BP patients followed at
various time points of their disease detected binding to
BP-specific intracellular epitopes at an early stage of
the disease in two out of five BP patients examined. Finally,
it is noteworthy that in a BP patient (BP62) in whom
autoantibody reactivity with NC16A domain was detectable
before the development of the disease, binding to an
additional intracellular epitope was found shortly after when
full-blown bullous lesions developed, supporting for the first
time an ‘‘intramolecular epitope spreading’’ phenomenon in BP.
In conclusion, by characterizing a series of epitopes of
BP180 targeted by anti-BP180 autoantibodies and provid-
ing a detailed epitope pattern in a large panel of BP patients,
our study provides novel insights into the autoimmune
response to BP180. Our approach may be useful to
characterize the autoimmune response in other autoim-
mune blistering disorders of the skin, such as in the
pemphigus group. The developed immunologic screening
procedure with BP180 epitopes on matrix constitutes a
rapid diagnostic tool that appears to have a sensitivity
higher than that obtained by the standard immunoblotting
procedure of keratinocyte extracts. By allowing the deter-
mination of an epitope pattern that reflects the clinical
phenotypes of BP, this approach might provide predictive
markers relevant for management of the patients. Prelimin-
ary data on the reactivity of some BP patients against
BP180 intracellular epitopes in an early stage of the disease
suggest a hitherto unrecognized importance of intracellular
epitopes in the initiation and development of disease.
Further characterization of epitope spreading in a larger
group of prospective patients is key to the understanding of
the dynamic of the immune response to BP180 and, hence,
of the pathogenesis of BP, and it is hoped that it will facilitate
the development of specific immunologic treatments.
Results
Construction and characterization of the BP180 random
epitope k library To characterize the epitope pattern of BP
serum samples, we prepared a phage l library of BP180
random peptides fused to the D capsid protein using the
l171loxP– vector. This bacteriophage contains the coding
sequence for the D protein carrying at its 30 end Spe I and
Not I restriction sites, which allow subcloning of cDNA
fragments of interest. The BP180 cDNA random fragments
generated by DNase I digestion were ligated to adapters A
and B with Spe I and Not I restriction sites, respectively, and
then cloned into the l171loxP–. The library complexity,
calculated as total number of independent clones, was
1.3  106. Control re-ligated vector yielded 5  103 plaques,
0.4% of the entire library, indicating that the vast majority of
the phages contained an insert. Random sampling, ampli-
fication, and sequencing of 50 plaques showed that each
clone contained a unique cDNA sequence between 30 bp
and 700 bp, with the most represented sequences in the
library being 201–300 bp long (Fig 1).
Figure1
The inserts in the BP180 random epitope library are unique and
range from 30 to 700 bp. (a) PCR amplification of 50 randomly
selected phage clones from the library. The inserts are different in
length and their size ranges from 30 bp to 700 bp. M, molecular weight
marker. (b) Diagram depicting the size and distribution of the inserts,
cloned in the bacteriophage l vector. The length of the more
represented inserts in the library varies between 201 and 300 bp.
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Epitope mapping of three anti-BP180 MoAb To test
whether the BP180 fragments are efficiently displayed on
the l capsid surface and to validate the random epitope
library, we first carried out an affinity selection using the
MoAb 1D1 and 233 binding to the ECD of BP180, as well as
the MoAb 1A8c directed against its ICD (Hirako et al, 1998).
Two rounds of affinity selection were performed and each
time the phages were plated as plaques and probed with
the same MoAb used for their enrichment. Eleven, 14, and
12 clones immunoreactive with MoAb 1A8c, 233, and 1D1,
respectively, were isolated. The recognized peptide
stretches were deduced on the basis of the corresponding
sequence of the cDNA inserts. Alignment and comparison of
the bound regions allowed us to precisely map the relevant
antigenic reactive sites (Fig 2). The MoAb 1A8c bound to a
nine AA stretch encompassing residues 155–163, the MoAb
233 reacted with a 26 AA stretch spanning residues 1118–
1143, whereas the MoAb 1D1 detected a 31 AA stretch
corresponding to residues 1357–1387 (Fig 2). In extension to
previous studies (Borradori et al, 1997; Hirako et al, 1998),
these findings allow us to substantially narrow the antigenic
sites recognized by the three utilized MoAb and validate the
random epitope library of BP180 used for screening.
Identiﬁcation of BP180 epitopes by afﬁnity selection of
the random epitope library Previous studies have shown
that human serum samples can be successfully employed
to select epitopes from an antigen random epitope l library
(Kuwabara et al, 1997). Therefore, to identify BP180-
specific epitopes, three rounds of biopanning of the
BP180 library were carried out utilizing 10 serum samples
obtained from BP patients (Table I). To isolate BP-
associated phages from the library pool, we used a three-
step procedure: (1) biopanning of the library with a BP
serum; (2) immunologic screening of the selected pool with
the same serum used in the selection; and finally (3)
counter-screening with 10 NHI control sera. The 10
randomly selected BP sera (Table I) used in the affinity
selections were all able to enrich specific BP180 epitopes
from the library. These selections resulted in the identifica-
tion of 15 epitopes spread over the entire BP180 molecule.
Eight of 15 epitopes (AA 120–160, AA 151–170, AA 176–
203, AA 266–343, AA 282–341, AA 299–354, AA 292–367,
and AA 353–399) mapped in the ICD, and seven epitopes
(AA 508–541, AA 567–622, AA 773–798, AA 915–985, AA
1080–1107, AA 1331–1404, and AA 1354–1406) were
located in the ECD (Fig 3a). The results of the l library
Figure 2
Mapping of the epitopes recognized by three anti-BP180 MoAb
markedly narrows the previously described recognized regions. (a)
Schematic representation of BP180: The hatched, dotted, and
shadowed boxes represent the regions recognized by MoAb 1A8c,
233, and 1D1 as previously described (Hirako et al, 1998). (b) The
previously mapped regions are aligned with the peptide sequences
affinity selected with the 1A8c, 233, and 1D1 MoAb. The positions of
the first and last amino acid of the selected peptides are indicated.
Each sequence was independently isolated with a frequency indicated
in parenthesis. The alignment allows us to define the recognized region
that is shared by all the phages selected with each MoAb. TM,
transmembrane domain.
Figure3
BP sera bind to the epitopes affinity selected from the BP180
random epitope library. (a) Schematic diagram representing BP180
and the position of the BP epitopes selected from the library using 10
BP sera. BP-specific epitopes, as assessed by subsequent immuno-
screening with 57 BP sera and 64 NHI sera, are shown as black lines,
whereas epitopes recognized with comparable frequency by both BP
and NHI sera are depicted as hatched lines. For each epitope, the AA
residues that define the antigenic sites are indicated. (b) Representative
immunoscreened filters. Positive signals are indicated (arrows) and
correspond to phages exposing BP180 peptides that were recognized
by the BP sera. The position of the epitopes in the matrix is depicted on
filter BP10: 1, epitope encompassing residues 266–343 (AA 266–343);
2, phage clone without any peptide exposed on its capsid surface; 3,
AA 567–622; 4, AA 282–341; 5, AA 299–354; 6, phage clone with
unrelated peptide 1; 7, AA 508–541; 8, AA 1080–1107; 9, AA 1331–
1404; 10, AA 292–367; 11, AA 176–203; 12, phage clone with unrelated
peptide 2; 13, AA 773–798; 14, AA 915–985; 15, AA 353–399; 16, AA
1354–1406; 17, AA 120–160; 18, AA 151–170. Control serum (NHI1)
does not show any positive signal.
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affinity selections demonstrate that this approach is useful
and efficient to isolate BP-related epitopes, confirm that BP
sera reactivity against BP180 is not restricted to the NC16A
domain, and identify several novel epitopes that narrow
previously described antigenic regions.
Reactivity of 57 BP sera against the selected epitopes
To further characterize the BP180 epitope pattern of anti-
BP180 autoantibodies, we assayed the reactivity of 57
additional BP sera, 17 pemphigus sera, and 64 NHI control
sera against the 15 selected epitopes. To this purpose, we
constructed a matrix that was immunoscreened with BP and
control sera (Fig 3b). Eight of 15 epitopes showed a
significantly higher frequency of reactivity with BP sera than
with NHI control sera, as assessed by Fisher’s exact
probability test (Table III). The 17 pemphigus serum samples
used as additional negative controls did not show any
reactivity with these eight epitopes except for epitope AA
915–985, which was recognized by a single pemphigus
serum (Table III). This finding was not unexpected, as
reactivity of pemphigus sera with BP180 has been rarely
reported (Schumann et al, 2000). Seven BP180 epitopes
(Table III) were recognized with comparable frequency by both
NHI and BP sera and hence were excluded from evaluation.
Thirty-four (59.6%) of the 57 tested BP serum samples
recognized the stretch AA 508–541 located within the
NC16A domain, a region previously shown to contain
immunodominant epitopes (Zillikens et al, 1997b). Thirty-
one of 57 (54.4%) BP serum samples, however, bound to
additional antigenic reactive sites of the ICD and ECD of
BP180. Specifically, whereas 21 (36.8%) BP sera recog-
nized epitopes of the ECD of BP180 other than the NC16A,
16 (28.1%) recognized epitopes on the ICD.
Within the ECD of BP180, the epitopes AA 915–985 and
AA 1080–1107, located in the mid-portion of the ECD, were
recognized by eight (14.0%) and five (8.8%) BP sera,
respectively (Table III). Furthermore, nine (15.8%) BP sera
concomitantly recognized two overlapping COOH terminal
regions of the ECD, AA 1331–1404 and AA 1354–1406 (Table
III). Two additional sera, BP11 and BP44, selectively bound
to epitope AA 1331–1404, but not to epitope AA 1354–1406,
bringing the recognition percentage of the larger fragment to
19.3%. Noteworthy, these two sera also showed binding
activity with epitope AA 1350–1387 selected using the MoAb
1D1 (data not shown). These findings indicate that BP11 and
BP44 sera bind to a distinct antigenic site encompassing
residues 1350–1353, which is absent from epitope AA 1354–
1406 but present in epitope AA 1331–1404. Based on these
results, it is very likely that the AA stretch 1331–1404
contains at least two distinct epitopes.
Within the ICD, epitopes AA 151–170, AA 176–203, and
AA 299–354 were recognized by seven (12.3%), six (10.5%),
and six (10.5%) BP sera, respectively (Table III). Two of the
six BP sera reacting to epitope AA 299–354 failed to
recognize the larger fragment AA 292–367. It is thus
conceivable that the epitope in the AA 299–354 fragment
is either conformational or masked in the AA 292–367
fragment. Noteworthy, the epitopes AA 151–170 and AA
1354–1406 bound by BP sera were also recognized by
MoAb 1A8c and 1D1, respectively, suggesting that these
regions are immunogenic in both mice and humans.
Together, 46 (80.7%) BP sera recognized at least one of
the eight epitopes selected from the BP180 library (Table III).
This reactivity was higher than that found against BP180
alone (61.8%) or both BP180 and BP230 (67.3%), as
assessed by immunoblotting analysis of keratinocyte extracts
(Table II). Six of 11 BP sera that did not react with any of the
eight BP-specific epitopes were positive by immunoblotting
analysis of keratinocyte extracts reacting with BP180 and/or
BP230 (Table II). The remaining five BP sera might recognize
an epitope not represented both in our library and in
denaturated keratinocyte extracts, or even a different antigen.
To demonstrate that BP sera reacted with BP180
epitopes also in a molecular context different from the D
protein of the l capsid surface, two representative epitopes
(AA 1080–1107 and AA 915–985) were then produced as
GST fusion proteins. BP serum samples that recognized the
selected epitopes on the phage also showed significant
reactivity with GST-1080 and GST-915 in a dot blot analysis
(data not shown).
Altogether our findings unequivocally demonstrate that,
in addition to NC16A, several other epitopes in both the ICD
and ECD of BP180 are recognized by a significant
percentage of BP serum samples.
BP patients with both skin and mucous membrane
involvement show reactivity with epitopes in the ECD of
BP180 As previous studies have suggested that IgG
autoreactivity with certain antigenic regions of BP180 is
associated with peculiar clinical findings (Balding et al, 1996;
Hofmann et al, 2002), we explored the potential relationship
between BP180 epitope pattern and clinical features. In
particular, we assessed whether our identified NC16A (AA
508–541) and C-terminus (AA 1331–1404) epitopes could be
associated with mucosal lesions, as recently reported for the
N- and C-terminus regions of BP180 ECD (residues 490–811
and 1351–1497, respectively) (Hofmann et al, 2002). The
results showed a significant correlation between the
presence of both skin and mucous membrane involvement
and reactivity with epitopes in the ECD of BP180 (p¼0.023)
(Table IV). Specifically, BP patients with mucosal involve-
ment showed more frequently (three of eight; 37.5%) an
autoantibody response to both the epitopes AA 508–541
and AA 1331–1404 than BP patients without mucosal
involvement (two of 43; 4.7%). Although based on a limited
number of BP patients these findings suggest that autoanti-
body reactivity with multiple regions of the ECD of BP180
relates to the development of mucosal lesions.
Finally, in the 39 serum samples obtained from BP before
treatment initiation IgG reactivity with either single or
grouped BP180 epitopes was not significantly related to
the duration of the disease. Noteworthy, there was no trend
for an increased binding activity of BP sera with intracellular
epitopes in the course of the disease. In contrast, although
the difference did not reach statistical significance, reactiv-
ity with intracellular epitopes appeared even higher in BP
patients with a disease duration of 3 mo (10 of 20; 50%)
than in those with a disease duration of more than 3 mo
(four of 19; 21%) (data not shown).
BP patients show a speciﬁc epitope pattern during the
disease course To evaluate the potential of our approach
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in studying the BP180 epitope pattern during the course of
disease, serum samples from five BP patients were
collected at various disease stages and analyzed by matrix
immunologic screening. The first patient, BP58, who fulfilled
from the beginning the diagnostic criteria for BP, exhibited
the same pattern of reactivity with both an intracellular (AA
282–343) and extracellular (AA 773–798) epitope from the
early pruritic nonbullous stage to the full-blown bullous
stage until therapy-induced clinical remission over a 31 mo
period (Table V). Two other patients (BP59 and BP60) in the
bullous phase of the disease showed reactivity with the
NC16A fragment (AA 508–541), which disappeared during
therapy-induced clinical remission (Table V). The remaining
two patients, BP61 and BP62, were first assessed in the
prodromal phase of the disease when diagnostic criteria for
BP were still unfulfilled (i.e., they did not exhibit tissue-
bound immune deposits along the BMZ). Whereas the BP61
serum did not show any reactivity, the BP62 serum reacted
with the NC16A fragment (AA 508–541) at this early stage.
When full-blown disease developed, BP62 serum, in
addition to the NC16A fragment, also bound to an
intracellular epitope of BP180 (AA 176–203), whereas
BP61 serum recognized the NC16A fragment as well as
various intracellular epitopes. The reactivity pattern of the
BP61 and BP62 sera remained then stable (Table V). These
preliminary results suggest that (1) BP patients show a
distinct BP180 epitope profile in the course of the disease,
and (2) binding to both the NC16A and intracellular epitopes
can be detected early in the course of the disease.
Materials and Methods
Patients and controls Ten randomly selected BP sera were used
to affinity select BP180 epitopes from the random epitope library
(Table I). Serum samples, used to study the reactivity with the
BP180 selected epitopes, were obtained from 57 BP patients, of
whom 39 had not begun any specific treatment and 14 were
treated at the time of blood draw (no information about the
treatment status of the remaining four patients was available)
(Table II). Forty-three of 57 BP patients presented only skin blisters
without any mucous membrane involvement, and eight also had
mucosal lesions in the absence of residual scarring (no information
about mucous membrane involvement of the remaining six
patients was available) (Table II). In addition, sera were collected
from five BP patients at various time points during the disease
course. The clinical diagnosis of BP was confirmed by direct
immunofluorescence (DIF) assay, showing a linear deposition of
IgG and/or C3 along the BMZ, and by indirect immunofluorescence
(IIF) assay, showing IgG autoantibodies binding the epidermal side
of 1 M NaCl split human skin (Tables I, II). Forty and 25 out of 65
serum samples recognized BP180 and BP230, respectively, by
immunoblotting analyses with human keratinocyte extracts as
substrate (Tables I, II). Controls included 17 pemphigus patient
sera positive by DIF and IIF (autoantibodies reacting with the
surface of epithelial cells of monkey esophagus) and sera from 64
normal healthy individuals (NHI) (age range 18–73 y). The study
was conducted in accordance to the Declaration of Helsinki
guidelines and approved by the IDI-IRCCS Ethic Committee; all
patients gave informed consent.
Monoclonal antibodies and immunologic reagents Mouse IgG1
monoclonal antibodies (MoAb) 1D1, 233, and 1A8c, which
recognize the ECD (1D1 and 233) and the ICD (1A8c) of BP180
(Hirako et al, 1998), were used to validate the BP180 random
epitope library. An alkaline phosphatase conjugated rabbit anti-
mouse IgG (H þ L) (Southern Biotechnology Associates, Birming-
ham, AL) and an alkaline phosphatase conjugated goat antihuman
IgG (Fc-specific) (Sigma, St Louis, MO) were used as secondary
antibodies in the immunologic screening procedure for the MoAb
and BP sera epitope mapping, respectively.
BP180 random epitope k library construction The human
BP180 cDNA (Borradori et al, 1997) cloned in the pCDNA3 vector
(Invitrogen, Carlsbad, CA) was partially digested with DNase I
(Roche Diagnostics, Basel, Switzerland). The digested DNA was
then fractionated by 1.5% agarose gel electrophoresis, and the
fragments from 50 bp to 500 bp were excised and purified with the
Wizard DNA purification system (Promega, Madison, WI). The ends
of these fragments were filled in with the T4 DNA polymerase (New
England Biolabs, Beverly, MA) and ligated using 400 units of the T4
DNA ligase (New England Biolabs) with 20-fold molar excess of
adapters A and B. The double strand adapter sequences were as
follows: A, forward 50-CTAGTGGCAGTGGTAGCGGC-30; reverse
50-GCCGCTACCACTGCCA-30, and B, forward 50-GCTGGTTTCA-
AGTGC-30; reverse 50-GGCCGCACTTGAAACCAGC-3.
The 16-mer and 15-mer oligos from adapters A and B,
respectively, were 50 phosphorylated. Unligated and self-ligated
adapters were removed by separation with 2% agarose gel
electrophoresis and fragments ligated to adapters were purified
with the Wizard DNA purification system (Promega). The purified
DNA fragments were ligated with the vector l171loxP– (Santi et al,
2000) (kindly provided by Dr A. Nicosia, IRBM, Pomezia, Italy),
digested with Spe I and Not I restriction enzymes. The ligation
mixture was then packaged using l packaging kit (Amersham
Biosciences, Piscataway, NJ) according to the manufacturer’s
instructions. The resultant phages were plated at 5  105 plaque-
forming units (pfu) per 150 mm plate on Escherichia coli strain BB4
(Stratagene, La Jolla, CA) and prepared as a lysate (Sambrook
et al, 1989).
Biopanning procedure The BP sera autoantibodies and the
MoAb epitope mapping were performed by coating 60 mm
diameter polystyrene dishes overnight at 41C with 1 mg per mL
Protein A (Amersham Biosciences) and 1 mg per mL rabbit
antimouse immunoglobulins (Dako, Carpinteria, CA), respectively,
Table IV. Relationship between the presence of mucosal involvement in BP patients and autoantibody response against epitopes
in the extracellular region of BP180
Mucosal involvement
– þ Total
AA 1331–1404þ  41 (95.3%) 5 (62.5%) 46 (90.2%)
AA 508–541a þ 2 (4.7%) 3 (37.5%) 5 (9.8%)
Total 43 (100%) 8 (100%) 51 (100%)
aA BP serum was considered positive when reacted against AA 1331–1404 and AA 508–541. p¼0.023 as determined by Fisher’s exact probability
test.
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in 2 mL of coating buffer (50 mM NaHCO3 pH 9). After two washes
with blocking solution (3% bovine serum albumin, 1% Triton in
1  phosphate-buffered saline (PBS)), the dishes were blocked
with 10 mL of the same solution for 2 h at 371C. BP sera (10 mL) or
hybridoma supernatants of the MoAb (10–40 mL) were preincu-
bated with gentle agitation for 30 min at 371C in 1 mL blocking
solution with 10 mM MgSO4 and 10 mL of BB4 bacterial extracts.
One hundred microliters of BP180 random epitope l library (about
1010 pfu) were then added to the preincubation mixture and
incubation was carried out for 1 h at 371C. This mixture was placed
on the Protein-A- or antimouse-immunoglobulin-coated dishes for
30 min at room temperature under gentle agitation. Unbound
phages were removed by extensive washing with 1% Triton, 10
mM MgSO4 in 1  PBS. Bound phages were eluted by incubating
the dish with BB4 cells for 20 min at room temperature. Cells
infected by phages were recovered and used for phage titration
and immunologic screening. The phages were then affinity
selected for two or three cycles (rounds).
Immunologic screening Phage plaques grown on BB4 cells were
blotted onto a nitrocellulose filter (Millipore, Bedford, MA). The filter
was washed three times for 10 min at room temperature with
washing solution (0.1% Triton in 1  PBS) and incubated with
blocking solution (5% skimmed milk, 0.1% Nonidet P-40 in
1  PBS) for 3 h at room temperature. Each BP serum (10 mL)
was preincubated with gentle agitation for 30 min at 371C in 4 mL
of blocking solution with 25 mL per mL of BB4 bacterial extracts
and 3.5  109 pfu per mL of l control phage (l171loxP–). This
mixture was added to the nitrocellulose filter and incubated under
gentle agitation overnight at 41C. Then, the filter was washed and
incubated with the appropriate alkaline phosphatase conjugated
secondary antibody for 1 h at room temperature. The filter was
washed eight times and then stained with 330 mg per mL of
nitroblue tetrazolium (NBT) and 165 mg per mL of 5-bromo-4-
chloro-3-indolyl phosphate (BCIP) (Roche Diagnostics) in substrate
buffer (100 mM NaCl, 100 mM TrisHCl pH 9.6, 5 mM MgSO4). The
DNA coding sequences of the epitopes exposed on phage clones
exhibiting positive immunostaining were amplified by PCR. The
forward primer 50-ACGTTCCGTTATGAGGATGT-30 and reverse
primer 50-CCACTACGTGAACCATCAC-30 were annealed upstream
and downstream of the insertion site of BP180 fragments in the
l171loxP–. The PCR cycle profile was 1 min at 941C, 1 min at 581C,
1 min at 721C for 30 cycles, followed by an elongation step of 10
min at 721C. The amplified products were purified with the High
Pure PCR product purification kit (Roche Diagnostics) sequenced
using the BigDye terminator cycle sequencing kit and run on an
automated sequencer ABI prism 377 (Applied Biosystems, Roche
Molecular Systems, Branchburg, NJ).
Matrix construction All positive phages displaying a BP180
epitope on their capsid surface were amplified by preparing a
phage lysate. Phages were peaked as a plaque on NZY plate with
BB4 starved cells poured with top agar and incubated overnight at
371C. The lysis spots obtained were blotted onto nitrocellulose
filter and immunoscreened with BP or control sera.
The immunologic screening procedure was performed as
described above using BP serum samples diluted 1:400 in
blocking buffer and an alkaline phosphatase conjugated goat
antihuman IgG (Fc-specific) (Sigma) diluted 1:2000 as secondary
antibody. A wild-type phage with no peptide exposed on its capsid
surface and two different phage clones displaying unrela-
ted peptides were always used as internal negative controls.
The results were confirmed by performing two independent
experiments.
Statistical analyses The Fisher’s exact probability test was used
to compare the frequencies of BP sera and NHI sera reactivity to
BP180 epitopes and to assess the relationship between clinical
findings and epitope pattern. A p value p0.05 was considered
significant.
Fusion protein production and dot blot analysis Two cDNA
fragments encoding the amino acids (AA) 1080–1107 and 915–985
of human BP180 were amplified by PCR using the BP180 cDNA as
template. The fragment AA 1080–1107 was amplified with the
sense primer 50-CGGGATCCCCTCCTCCATCTCTTC-30 and anti-
sense primer 50-GGAATTCTCAAGGGCCCATCAAGTAC-30. The
fragment AA 915–985 was amplified with the sense primer 50-
CGGGATCCCCGGTCCCAAG-30 and antisense primer 50-
GGAATTCTCATGATCCCCCTTCAG-30. The underlined sequences
represent the BamH I and EcoR I restriction sites. After BamH I and
EcoR I digestion, the fragments were cloned into pGEX-3X
(Amersham Biosciences) in order to obtain glutathione S-transfer-
ase (GST) -1080 and -915 fusion proteins. Recombinant clones
were expressed in the E. coli strain DH5a (Invitrogen) and purified
by affinity chromatography using Glutathione-Sepharose 4B
(Amersham Biosciences).
GST (600 ng) and molar equivalent amounts of GST-1080 or
GST-915 were dot blotted onto nitrocellulose membrane Hybond-
C (Amersham Biosciences). Filters were incubated, first with
blocking solution for 1 h at room temperature, and then overnight
at 41C with 30 mg per mL GST, 100 mL per mL of DH5a bacterial
extracts, and 1:100 dilution of each tested serum. After washing,
the filters were incubated with the appropriate alkaline phospha-
tase conjugated secondary antibody for 1 h at room temperature
and developed with NBT and BCIP (Roche Diagnostics).
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